RAPT logo

RAPT Therapeutics (RAPT) Company Overview

Profile

Full Name:

RAPT Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 31, 2019

Indexes:

Not included

Description:

RAPT Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases. They aim to create targeted treatments that improve patient outcomes by harnessing the body's immune system. Their research emphasizes precision medicine and advancing drug candidates through clinical trials.

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Mar 6, 2025

Recent annual earnings:

Mar 6, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Mar 10, 25 HC Wainwright & Co.
Buy
Dec 26, 24 HC Wainwright & Co.
Buy
Nov 25, 24 HC Wainwright & Co.
Neutral
Nov 12, 24 Wells Fargo
Overweight
Nov 12, 24 HC Wainwright & Co.
Neutral
Nov 11, 24 JP Morgan
Underweight
Sep 9, 24 UBS
Neutral
Aug 20, 24 HC Wainwright & Co.
Neutral
Jul 23, 24 HC Wainwright & Co.
Neutral
May 14, 24 Wolfe Research
Peer Perform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for RAPT Therapeutics?
  • Does RAPT Therapeutics pay dividends?
  • What sector is RAPT Therapeutics in?
  • What industry is RAPT Therapeutics in?
  • What country is RAPT Therapeutics based in?
  • When did RAPT Therapeutics go public?
  • Is RAPT Therapeutics in the S&P 500?
  • Is RAPT Therapeutics in the NASDAQ 100?
  • Is RAPT Therapeutics in the Dow Jones?
  • When was RAPT Therapeutics's last earnings report?
  • When does RAPT Therapeutics report earnings?
  • Should I buy RAPT Therapeutics stock now?

What is the ticker symbol for RAPT Therapeutics?

The ticker symbol for RAPT Therapeutics is NASDAQ:RAPT

Does RAPT Therapeutics pay dividends?

No, RAPT Therapeutics does not pay dividends

What sector is RAPT Therapeutics in?

RAPT Therapeutics is in the Healthcare sector

What industry is RAPT Therapeutics in?

RAPT Therapeutics is in the Biotechnology industry

What country is RAPT Therapeutics based in?

RAPT Therapeutics is headquartered in United States

When did RAPT Therapeutics go public?

RAPT Therapeutics's initial public offering (IPO) was on October 31, 2019

Is RAPT Therapeutics in the S&P 500?

No, RAPT Therapeutics is not included in the S&P 500 index

Is RAPT Therapeutics in the NASDAQ 100?

No, RAPT Therapeutics is not included in the NASDAQ 100 index

Is RAPT Therapeutics in the Dow Jones?

No, RAPT Therapeutics is not included in the Dow Jones index

When was RAPT Therapeutics's last earnings report?

RAPT Therapeutics's most recent earnings report was on Mar 6, 2025

When does RAPT Therapeutics report earnings?

The next expected earnings date for RAPT Therapeutics is May 9, 2025

Should I buy RAPT Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions